Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    EP07.01 - Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical
    • +

      EP07.01-021 - Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy

      Presenter: Sara Manglaviti

      • Abstract

      Loading...

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-006 - Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy

      Presenter: Alessandro De Toma

      • Abstract

      Loading...

  • +

    MA10 - Updates in Thymoma

    • 14:45 - 15:45
    • 8/08/2022
    • Location: Hall C8
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies
    • +

      MA10.07 - Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173)

      15:12 - 15:17  |  Presenter: Claudia Proto

      • Abstract

      Loading...